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Rapid Communication 
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Neurofibromin, the product of the neurofibromatosis 
type 1 (NF1) gene, is a -250 kDa protein expressed 
predominantly in cortical neurons and oligodendro- 
cytes in the central nervous system (CNS) and 
sensory neurons and Schwann cells in the peripheral 
nervous system (PNS). To gain insight into the 
biological role of neurofibromin in Schwann cells, the 
modulation of NFZ gene expression in a Schwann cell 
line (MT,Hl) stimulated to either proliferate or 
differentiate in response to agents that elevate 
intracellular cAMP was examined. Untreated cells 
and cells exposed to mitogenic doses of forskolin 
(1-10 pM) or 8-bromo-CAMP (0.1 mM) expressed 
low levels of NFZ mRNA and the protein was barely 
detectable. High doses of forskolin (100 pM) or 
8-bromo-CAMP (1 mM) induced the expression of 
both myelin Yo protein and neurofibromin with an 
identical time course. Although NFl mRNA levels 
peaked within 1-6 hr, the rise in neurofibromin was 
not apparent until 2 4 4 8  hr and peaked 72 hr after 
treatment. Po and neurofibromin were also coin- 
duced by cell-cell contact in high density, untreated 
cultures. Moreover, differentiation initiated by either 
cAMP stimulation or high density culture conditions 
was associated with predominant expression of the 
type 2 NFl mRNA isoform. In contrast, type 1 NFL 
mRNA isoform expression was observed in untreated 
Schwann cells or those stimulated with mitogenic 
doses of forskolin or 8-bromo-CAMP. A switch from 
the type 1 neurofibromin that can efficiently down- 
regulate p2l-ras to the type 2 isoform with reduced 
activity may facilitate a p21-ras signaling pathway 
associated with Schwann cell differentiation. 
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INTRODUCTION 
Von Recklinghausen neurofibromatosis or neurofi- 
bromatosis type 1 (NF1) is a common autosomal domi- 
nant disorder affecting approximately 1 in 3,500 individ- 
uals (Riccardi, 1991). Although there are a variety of 
different tissue abnormalities, nearly all adult patients 
with NF1 have neurofibromas (Riccardi, 1981). These 
are benign tumors which contain predominately 
Schwann cells (60-85%) with fewer numbers of fibro- 
blasts, perineurial cells, mast cells, pericytes, and vas- 
cular elements (Peltonen et al., 1983). When examined 
in vitro, Schwann cells from neurofibromas were found 
to have invasive properties and promote angiogenesis 
indicative of a preneoplastic state (Sheela et al., 1990). 
In addition, Schwann cells within neurofibromas are 
more likely to undergo malignant transformation into 
neurofibrosarcomas (Bader, 1986). 
The gene for NFl encodes an 11-13 kb mRNA 
expressed in all tissues although in varying amounts 
(Cawthon et al., 1990; Viskochil et al., 1990; Wallace et 
al., 1990; Xu et al., 1990b). Two alternatively spliced 
mRNA isoforms of N F l  have been identified and termed 
type 1 and type 2 (Andersen et al., 1993; Nishi et al., 
1991). The type 2 isoform contains an additional 63 base 
pairs, absent in the type 1 isoform, and is predominantly 
expressed in differentiated neuronal tissues. The NF1 
gene product, termed neurofibromin, migrates as a -250 
kDa protein on sodium dodecyl sulfate (SDS)-polyacryl- 
amide gels and is expressed in greatest quantities in the 
nervous system, spleen, and kidney (Daston et al., 1992; 
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experiments, cells were plated at 2.5 X 106 cells/100 
mm dish (100% confluent). 
DeClue et al., 1991; Gutmann et al., 1991). Through 
comparative sequence analysis, neurofibromin was 
found to share homology with a family of proteins in- 
volved in the regulation of p21-ras (Xu et al., 1990b). 
These proteins, termed GTPase-activating proteins 
(GAPS), accelerate the conversion of p21-ras from an 
active, GTP-bound state to an inactive, GDP-bound state 
(McCormick, 1989; Wigler, 1990). The isolated GAP- 
related domain (GRD) of neurofibromin has been shown 
to function in both yeast and mammalian systems (Bal- 
lester et al., 1990; Martin et al., 1990; Xu et al., 1990a). 
To understand the biological basis for the various 
tissue abnormalities in NF1, it will be essential to char- 
acterize the function of neurofibromin in affected cell 
types. Schwann cells express relatively high amounts of 
neurofibromin and appear to be particularly vulnerable to 
NFI gene defects. To investigate the biological role of 
neurofibromin in Schwann cells, we examined whether 
changes in Schwann cell function are associated with 
alterations in NFl gene expression. At rclatively low 
doses, agents that elevate intracellular CAMP levels have 
been shown to stimulate mitosis in cultured Schwann 
cells, whereas high concentrations induce a differenti- 
ated phenotype characterized by increased expression of 
myelin lipids and proteins (Morgan et al., 1991; Sobue 
and Pleasure, 1984; Sobue et al., 1986). Using a well- 
characterized Schwann cell line (Peden ct al., 1989, 
1990; Tennekoon et al., 1987), we found that differen- 
tiation was associated with increased expression of NFI 
mRNA and neurofibromin as well as the predominant 
expression of the type 2 isoform. This switch in NFl 
isoform expression may facilitate a p2 l-ras-mediated 
signal transduction pathway involved in Schwann cell 
differentiation. 
MATERIALS AND METHODS 
MT,H1 Schwann Cell Line 
The MT4H1 Schwann cell line was derived by 
transfecting primary rat Schwann cells with the SV40 
large T antigen under the control of a synthetic, metal- 
regulated promoter (Peden et al., 1989). To expand the 
population, cells were grown in Dulbecco’s modified 
Eagle’s medium (DMEM) with 10% heat-inactivated fe- 
tal bovine serum, 200 pg/ml G4 18, and 100 pM ZnCI,. 
Cells replated in medium without ZnC1, were treated 
5-10 days later when large T antigen is not detectable 
(Peden et al., 1989). Forskolin (Sigma, St. Louis, MO), 
dideoxy-forskolin (Calbiochem, La Jolla, CA), 8- 
bromo-CAMP (Sigma), or diluent alone was added for 
various intervals of time and at different concentrations. 
To control for the effects of cell density, MT4H1 
Schwann cells were replated at 1 X lo6 cells/100 mm 
dish (40% confluent) 48 hr before harvest. For some 
Antibodies and DNA Probes 
Myelin Po rabbit antiserum was kindly provided by 
Dr. Bruce Trapp (Johns Hopkins Medical School) and 
the galactocercbroside (Galc) rabbit antiserum was ob- 
tained from Advanced Immunochemical s (Los Angeles, 
CA). The a-tubulin monoclonal antibody was obtained 
from Sigma and the neurofibromin GI antipeptide anti- 
body (residues 1400-1419) has been previously de- 
scribed (Basu et al., 1992). The 1.2 kb P5 probe (nuclc- 
otides 6624-7847) was derived from an NFI cDNA 
clone obtained from a cauda equina cDNA library (Wal- 
lace et al., 1990). 
Growth Rate 
Cells were replated in the absence of ZnCI, and 
5-10 days later seeded at 25-30% confluence in 6 or 12 
well plates. Low doses of forskolin (1-10 pM) or 
8-bromo-CAMP (0.1 mM) were added in fresh feeding 
medium after the cells had attached. After 24 or 48 hr of 
treatment, the cells were detached with trypsin and 
counted in a hemocytometer. Each condition was as- 
sayed in triplicate in three separate experiments. 
Immunofluorescence 
Cells fixed in 4% formaldehyde and permeabilized 
in 100% methanol for 5 min at -20°C were stained by 
indirect immunofluorescence (Tennekoon et al., 1987; 
Gregory et al., 1993). Antibodies were diluted 150-  
1:200 in medium containing 10% serum and photo- 
graphed using a Zeiss Axiophot microscope with Ekta- 
chrome 400 film. 
Western Immunoblotting 
Cells were rinsed in cold phosphate-buffered saline 
(PBS) and scrape-harvested in PBS. The cell pellet was 
lysed in RIPA buffer containing I %  aprotinin, 1% leu- 
peptin, and 1 mM phenylmethylsulfonyl fluoride on ice 
for 10 min before disruption through a 25 gauge needle. 
The lysatc was then clarified by centrifugation at 14,000 
rpm for 15 min at 4°C and the protein concentration of 
the supernatant was determined using the BioRad protein 
assay (BioRad Laboratories, Hercules, CA). Protein 
samples were separated on 7.5% SDS-polyacrylamide 
gels (100 pgilane) and transferred to Immobilon (Gut- 
mann et al., 1991). Membranes were incubated over- 
night at 4°C with antibodies diluted in Tris-buffered sa- 
line containing 5% nonfat dry milk and developed using 
alkaline phosphatase-conjugated secondary antibodies 
(Gutmann et al., 1991), or with horseradish peroxidase- 
conjugated secondary antibodies and the ECL detection 
system (Amersham, Arlington Heights, IL). To measure 
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neurofibromin levels, the top half of the membrane was 
incubated with G1 antibodies (1:200) and the bottom half 
with anti-a-tubulin antibodies (1 : 1,000) to assess varia- 
tion in sample loading. Antibodies to Po (1500) were 
applied to separate membranes. 
Northern Blotting 
Total RNA was isolated from cells after rinsing the 
dishes in cold PBS using a modification of the acid- 
phenol method (RNAzol B; Tel-Test, Tnc., Friendswood, 
TX). RNA concentrations were calculated by ultraviolet 
(UV) absorption and stored at -70°C in DEPC-treated 
water. Samples of total RNA (20 kg/lane) were sepa- 
rated on 1 .2% agarose-0.37 M formaldehyde gels for 3.5 
hr, stained briefly with ethidium bromide, and photo- 
graphed. RNA was transferred onto nitrocellulose mem- 
branes (Hybond, Amersham) and cross-linked by UV 
exposure (Wallace et al., 1990). The 1.2 kb EcoRI frag- 
ment of plasmid P5 and a p-actin cDNA probe were 
labeled with 32P-dCTP using random hexamers and pu- 
rified by spin-column chromatography. Membranes were 
prehybridized in 1 X Denhardt’s solution (1% SDS/0.2 
M dextran sulfate/l M NaC1) containing 100 pg/ml 
salmon sperm DNA for 3-12 hr at 65”C, and then hy- 
bridized with the probe overnight at 65°C. Membranes 
were washed in 2 x SSC, 0.1 % SDS, and exposed to 
film at -70°C for 2-5 days. Relative changes in N F l  
expression were quantitated by scanning densitometry 
and the values adjusted to compensate for variations in 
the amount of total RNA between lanes. 
RNA Isoform Analysis 
The NFI type 1 and type 2 mRNA isoforms were 
distinguished using primers which span the 63 bp inser- 
tion in the GRD (Andersen et al., 1993; Nishi et al., 
199 1): 5’-GGAACCTCCTTCAGATGACAG-3’ (for- 
ward) and 5 ’-CATGATTGGCAATGCTCTGAA-3’ (re- 
verse). Total RNA (2 pg) was reverse transcribed using 
Moloney MuLV Superscript reverse transcriptase (Boeh- 
ringer Mannheim, Indianapolis, IN). The resulting 
cDNA was amplified by the polymerase chain reaction 
(PCR) for 30 cycles using a 60°C annealing step (Nishi et 
al., 1991). The PCR products were analyzed on a 8% 
polyacrylamide gel stained with ethidium bromide. 
RESULTS 
Effect of cAMP on Cell Growth Rate 
The doubling time of MT,Hl Schwann cells was 
24 hr in the presence of ZnCl,, but increased to 56 hr 
after maintaining the cells for 5 days without ZnC1,. 
Treating cells grown in the absence ZnC1, with low doses 
of forskolin or cAMP analogs stimulated mitosis with a 
relatively rapid onset. Within 48 hr, low doses of for- 
skolin (1-10 pM) or 8-bromo-CAMP (0.1 mM) had sig- 
nificantly increased the number of cells per well by 23- 
54% in 3 separate experiments ( P  > 0.05, Student’s 
t-test). 
Effect of cAMP on Cell Phenotype 
Treatment of MT,H1 cells with either 100 pM for- 
skolin or 1 mM 8-bromo-CAMP induced a rapid change 
in the morphological appearance of the cells which is 
most pronounced with forskolin (data not shown). The 
cells initially assumed a more elongated, bipolar shape, 
but after 48 hr of continued treatment, many cells ap- 
peared enlarged and flattened coincident with an increase 
in myelin Po expression. Figure 1 shows MT,Hl 
Schwann cells 72 hr after treatment (B) compared to 
untreated cells (A) stained for Po by indirect immunoflu- 
orescence. Western immunoblotting demonstrates the 
change in myelin Po levels over time (C). Po expression 
was not altered by treatment with diluent alone, dideoxy- 
forskolin (an analog of forskolin without CAMP-stimu- 
lating properties), 0.1 mM 8-bromo-CAMP, or 1-10 pM 
forskolin (data not shown). Similarly, only the MT,H1 
cells treated with high concentrations of 8-bromo-CAMP 
or forskolin stained intensely for Galc, another indicator 
of Schwann cell differentiation (not shown). 
Effect of cAMP on NFl mRNA Levels 
Samples of total RNA from MT,H1 Schwann cells 
stimulated with 1-100 pM forskolin for various time 
intervals were analyzed by Northern blotting with the 1.2 
kb P5 probe. The autoradiogram after a 72 hr exposure is 
shown in Figure 2A, while the ethidium bromide-stained 
gel before transfer is shown in Figure 2B. Relative 
changes in NFI expression were quantitated by scanning 
densitometry and the values adjusted to compensate for 
variations in the amount of total RNA between lanes 
(Fig. 2C). In addition, probing with the p-actin cDNA 
probe demonstrated approximately equal loading (data 
not shown). Northern blot analysis revealed a rapid in- 
duction of NFl mRNA in response to 100 pM forskolin 
beginning at I hr and remaining elevated for at least 24 
hr. Much smaller increases in NFZ mRNA occurred after 
treatment with the lower doses. Overexposure of these 
filters demonstrates low level expression of N F l  mRNA 
in untreated MT,H1 cells. Identical results were obtained 
on several occasions with forskolin and cAMP analogs 
(data not shown). 
Effect of cAMP on Neurofibromin Expression 
No change in neurofibromin expression was de- 
tected at 1, 6, or 24 hr after treatment with 1 mM 
8-bromo-CAMP even though NFl mRNA was markedly 
increased (data not shown). However, neurofibromin ex- 
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IC, it was apparent that the time course of neurofibromin 
induction was identical to that of the myelin Po protein. 
Increased neurofibromin expression was also seen with 
100 FM forskolin (data not shown); however, low doses 
of cAMP analogs or forskolin failed to induce the ex- 





Fig. 1. Expression of myelin P, protein in MT,H1 Schwann 
cells treated with 1 mM 8-bromo-CAMP. The expression of the 
myelin Po protein was examined in MT4Hl Schwann cells by 
indirect immunofluorescence. Untreated cells stained weakly 
for myelin P, protein (A), whereas cells treated with 1 mM 
8-bromo-CAMP for 72 hr were brightly positive (B). C: The 
relative change in Po expression over time in response to ele- 
vating intracellular cAMP was also assessed by Western im- 
munoblotting. The increase in P, expression occurred after 
24-48 hr of treatment. 
pression was induced by 48 hr and the levels peaked 72 
hr after treatment (Fig. 3A). Since tubulin levels were 
not affected, the relative changes in neurofibromin ex- 
pression over time were adjusted to compensate for vari- 
ations in loading (Fig. 3B). When compared to Figure 
NFZ mRNA Isoforms in Differentiating MT,H1 
Schwann Cells 
Treatment of MT,H1 Schwann cells at 40-50% 
confluence with 1 .0 mM 8-bromo-CAMP resulted in pre- 
dominant expression of the type 2 isoform (Fig. 4, lane 
4), whereas cells treated with low doses of untreated 
cells expressed the type 1 isoform (lanes 2 and 3 ) .  The 
type 2 NF1 mRNA isoform was also predominant in 
confluent, untreated cultures (lane 1). Although this 
PCR analysis is not absolutely quantitative between sam- 
ples, within a given sample the relative amounts of the 
two isoforms are accurately reflected. No changes in the 
relative amount of pl2O-GAP RNA were detected by 
PCR in these samples (data not shown). Therefore, dif- 
ferentiation initiated by increasing intracellular cAMP or 
by cell-cell contact in MT4H1 Schwann cells is associ- 
ated with a switch in NFI isoform expression from the 
type 1 to type 2 mRNA isoform. 
DISCUSSION 
NFl is a disease in which abnormal Schwann cell 
growth presumably contributes to the development of 
neurofibromas. To understand how NFI gene defects re- 
sult in abnormal growth, it will be essential to charac- 
terize the biological function of neurofibromin in 
Schwann cells. In vivo, Schwann cells are normally 
found only in association with axons which strictly con- 
trol their function, although the signaling pathways and 
molecules involved are largely unknown. However, the 
cAMP pathway has been implicated in the regulation of 
growth and maturation in several cell types, and agents 
that increase intracellular cAMP concentration in cul- 
tured Schwann cells stimulate either mitosis or expres- 
sion of the differentiated phenotype, depending on con- 
centration and culture conditions (Morgan et al., 1991; 
Sobue and Pleasure, 1984; Sobue et al., 1986). To in- 
vestigate the role of neurofibromin in Schwann cell func- 
tion, we used the MT,Hl Schwann cell line which was 
immortalized with SV40 large T antigen regulated by a 
synthetic, metal-inducible promoter (Peden et al., 1989). 
Because T antigen expression is low and tightly regu- 
lated, T antigen is not detectable in the absence of the 
inducer and MT4H1 cells can fully differentiate to pro- 
duce myelin (Peden et al., 1990). 
We demonstrate here that MT,H1 cells respond in 
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Fig. 2 .  Differentiating MT,H1 Schwann cells increase NFI 
mRNA levels. A: Northern blot analysis using the P.5 cDNA 
probe demonstrates increased expression of NFI mRNA in 
response to 100 pM forskolin. Much smaller increases were 
observed with 1-10 p M  doses of forskolin. Identical results 
were obtained with 8-bromo-CAMP stimulation. B: Approxi- 
mately equal loading of RNA is demonstrated by ethidium 
a similar manner as primary Schwann cells to agents that 
increase CAMP levels. Low doses of forskolin (1-10 
pM) or 8-bromo-CAMP (0.1 mM) were mitogenic (cell 
numbers increased 23 -54% in 48 hr), whereas high 
doses (1 00 pM forskolin or 1 mM 8-bromo-CAMP) were 
necessary to induce the expression of myelin Po protein 
or Galc. Expression of Po protein is frequently used as an 
indicator of the differentiated phenotype which is char- 
acterized by coordinated expression of myelin-related 
components (including Po, myelin basic protein, and 
Galc) with repression of glial fibrillary acidic protein, 
N-cellular adhesion molecule, and the p75 nerve growth 
factor receptor (Morgan et al., 1991; Sobue and Plea- 
sure, 1984; Sobue et al., 1986). When identical samples 
were examined for N F l  gene expression, untreated 
MT4H1 Schwann cells and those exposed to mitogenic 
18 24 
bromide staining of the gel. C: Quantification of the NFI 
mRNA levels relative to the amount of total RNA by scanning 
densitometry indicated that NFI mRNA was rapidly induced 
and remained elevated for at least 24 hr. Open boxes denote 
100 pM forskolin, while the diamonds and closed boxes de- 
note 10 and 1 pM forskolin, respectively. 
doses of forskolin or 8-bromo-CAMP were found to ex- 
press low levels of the type 1 N F l  mRNA isoforrn, with 
barely detectable levels of neurofibromin expression. 
However, high doses of forskolin or 8-bromo-CAMP in- 
duced the expression of neurofibromin with a time 
course identical to that of myelin Po protein, NFZ mRNA 
levels peaked within 1-6 hr after treatment, but the rise 
in neurofibromin was not apparent until 24-48 hr and 
peaked at 72 hr. The lag in protein induction suggests 
that neurofibromin expression may be translationally 
controlled to coordinate with differentiation. 
Primary Schwann cells have also been shown to 
differentiate in growth-arrested, confluent cultures (Mor- 
gan et al., 1991), and we found that Po and neurofibro- 
min were coinduced in high density, untreated cultures 
of MT4H 1 cells. Moreover, differentiation initiated by 
Neurofibromin in Differentiating Schwann Cells 221 
A 2 .u
0.1 mM cAMP 1.0mMcAMP 8 
I I I  1 






0 24 48 72 96 
hours 
Fig. 3. Differentiating MT,H1 Schwann cells increase expres- 
sion of neurofibromin. A: Western irnrnunoblotting showed 
that cells stimulated to differentiate in response to 1 mM 
8-bromo-CAMP upregulated neurofibromin (nf) expression af- 
ter 24-48 hr of treatment. Lower concentrations (0.1 mM) did 
not alter neurofibromin levels. B: To control for variations in 
protein loading, a portion of the same membrane was incubated 
with an a-tubulin (tu) monoclonal antibody. C: Quantification 
of neurofibromin levels relative to the amount of tubulin by 
scanning densitomelry indicated that expression peaked 72 hr 
after treatment. 
either elevated cAMP levels or cell-cell contact was cor- 
related with the specific induction of the type 2 isoform 
of N F l .  A switch in neurofibromin isoform expression 
from type 1 to type 2 has previously been reported to 
occur during neuronal differentiation of neuroblastoma 
cells (Nishi et al., 1991). The type 2 isoform contains a 
63 base pair insertion in the neurofibromin GAP-related 
domain (Nishi et al., 1991) and has markedly reduced 
GTPase activity as demonstrated by experiments in yeast 
and in vitro GAP assays (Andersen et al., 1993). The 
type 2 GAP-related domain also appears to bind more 
tightly to p21 -ras and conceivably could compete with 
the type 1 form for p21-ras (Andersen et al., 1993). 
Our results suggest the possibility that expression 
of the type 2 isoform may facilitate a p21-ras signal 
transduction pathway during Schwann cell differentia- 
tion. Introduction of oncogenic p2 l -ras has previously 
been shown to inhibit DNA synthesis in Schwann cells, 
and expression of the v-H-ras causes growth arrest in 
either the G ,  or G,/M phase of the cell cycle (Ridley et 
al., 1988). Growth arrest appears to be a prerequisite for 
cellular differentiation and induction of the myelin-re- 
lated phenotype in Schwann cells negatively correlates 
with mitosis since individual Schwann cells expressing 
high levels of Po do not synthesize DNA (Morgan et al., 
1991). It is not known whether activation of p21-ras 
alters the Schwann cell phenotype; however, activation 
of p21-ras is sufficient to trigger growth arrest and neu- 
ronal differentiation of rat PC 12 pheochromocytoma 
cells (Bar-Sagi and Feramisco, 1985; Noda et a]., 1985; 
Hagag et al., 1986). 
Neurofibromin is currently thought to function as a 
tumor suppressor gene product, and it has been sug- 
gested that abnormal growth of Schwann cells in neu- 
rofibromas is related to inadequate regulation of p2 l-ras. 
In experiments with malignant neurofibrosarcoma cells 
(presumably Schwann cells), barely detectable levels of 
neurofibromin and increased levels of activated GTP- 
222 Gutmann et al. 
GRD type 2 
GRD type 1 





- 0  
0 ,  
- 310 nt 
= 281/271 nt 
- 234 nt 
Fig. 4. Isoform analysis of NF1 mRNA in MT,HI Schwann 
cells. Total RNA was extracted and reverse transcriptase was 
used to convert mRNA into cDNA. The relative amount of the 
type 1 and type 2 mRNA isoforms in each sample was deter- 
mined by PCR. Subconfluent cultures (1.0 X 10' cells/l0 cm 
dish) and cells stimulated with 1.0 mM 8-bromo-CAMP ex- 
pressed predominantly the type 2 isoform; untreated cells or 
cells stimulated with 0. I mM 8-bromo-CAMP expressed the 
type 1 isoform. Untreated cells in confluent cultures (2.5 X 
106/10 cm dish) also expressed more type 2 than type 1. 
bound p21-ras were demonstrated (Basu et al., 1992; 
DeClue et a]., 1992). Reintroduction of the GAP-related 
domain of neurofibromin into these malignant Schwann 
cells decreased the levels of activated p21-ras and dra- 
matically slowed their growth rate, suggesting that ma- 
lignant transformation in these cells resulted, at least in 
part, from elevated levels of activated p2 1 -ras due to the 
absence of neurofibromin (Basu et al., 1992; DeClue et 
al., 1992). 
Since experiments in nontransformed Schwann 
cells indicate that p21-ras activation is involved in 
growth arrest, mutations in the NFl  gene that affect the 
ability of neurofibromin to regulate p2 1 -ras would be 
predicted to block cell growth and would not explain 
tumor development. However, nuclear oncogenes in- 
cluding c-myc, adenovirus EIA, and SV40 large T an- 
tigen act cooperatively with oncogenic H-ras to prevent 
p21-ras-mediated growth arrest and transform rat 
Schwann cells (Ridley et al., 1988). The effects of p21- 
ras may be similarly altered in malignant Schwann cells. 
Loss of heterozygosity for markers on the short arm of 
chromosome I7 involving the p53 tumor suppressor gene 
has been found in several neurofibrosarcornas (Menon et 
al., 1990), and this and other alterations in combination 
with neurofibromin loss may play a role in the progres- 
sion towards malignancy. 
Given that the results presented here are consistent 
with the hypothesis that p2 1 -ras activation is associated 
with Schwann cell differentiation, how can mutations in 
the NF1 gene cause abnormal cell growth if unregulated 
p21-ras is not entirely responsible? The most likely ex- 
planation is that neurofibromin has other functions be- 
side p2 1 -ras regulation. We have found that neurofibro- 
min associates with cytoplasmic microtubules in a 
number of cell types, including Schwann cells (Gregory 
et al., 1993; Gutmann et al., 1991a,b). It also appears 
that tubulin physically interacts with neurofibromin 
through the GAP-related domain and that this interaction 
significantly reduces the ability of neurofibromin to reg- 
ulate p21-ras (Bollag et al., 1993). Given this associa- 
tion, neurofibromin may connect p21 -ras regulation with 
such important microtubule-mediated functions as the 
control of cell shape. The precise role of neurofibromin 
and the function of its isoforms in the Schwann cell are 
likely to be complex. Future studies aimed at determin- 
ing the interaction between neurofibromin, p21 -ras, and 
microtubules in differentiating Schwann cells should ul- 
timately lead to a better understanding of tumor devel- 
opment in patients with NFI . 
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